Tools for Studying T-cell Activation and TCR Signaling
T-cell activation is a fundamental process of adaptive immunity and plays a central role in developing next-generation immunotherapies. Following antigen recognition by the T cell receptor (TCR), a cascade of intracellular signaling events drives naive T-cell activation, proliferation, and differentiation into effector and memory T cells. The magnitude and duration of signals can affect T-cell response outcomes. Fine-tuning T-cell activation to optimize adaptive immunity has emerged as a central objective in immunotherapy development, particularly in cancer.
Advances in immuno-oncology have led to the emergence of innovative therapeutic strategies, including bispecific T-cell engagers and adoptive cell therapies. Such approaches require robust and physiologically relevant tools to evaluate T-cell activation, antigen specificity, signaling pathways, and functional responses. Primary T cells are the most physiological cellular model, but the high variability in donors' genetics and steady-state immunity presents major robustness limitations. Consequently, standardized high-throughput platforms, such as engineered Jurkat reporter cell lines, have emerged as powerful tools for reproducible assessment of TCR specificity, avidity, and function.
InvivoGen provides a comprehensive portfolio of products to support T-cell research and therapeutic development, including:
- Reporter T Cells: Cell-based reporter systems for monitoring key signaling pathways downstream of T-cell receptor (TCR) activation, including NFAT, NF-κB, and IRF.
- TCR Reporter T Cells: Engineered TCR-knockout reporter cells lines for investigating antigen-specific T-cell activation and TCR-dependent signaling mechanisms.
- T-cell Engager Bispecific Antibodies: A family of recombinant bispecific antibodies (bsAbs) designed to evaluate T-cell redirection, activation, and effector functions against cancer cells expressing clinically relevant targets, such as CD19 and BCMA.
- T-cell Expansion Tools: Recombinant bioactive cytokines and a bispecific T-cell activation antibody that support the expansion, proliferation, and maintenance of primary T cells for research and cancer immunotherapy studies.
All our cell lines are extensively tested for viability, stability, biological activity, and absence of mycoplasma to ensure strong and reproducible results. Moreover, we provide detailed handling and experimental procedures for all cell lines, to minimize the need for optimization or troubleshooting by the end-user.
